Science
Are 'deaths of despair' really more common for white Americans? A UCLA report says no
Nakeya Fields has seen how the stresses that come with being Black — racial injustice, financial strain, social isolation — can leave people feeling hopeless and push some into substance abuse.
It’s one of the reasons the Pasadena social worker started offering “therapeutic play” gatherings for Black mothers like herself and children.
“I’m trying to host more safe spaces for us to come and share that we’re suffering,” the 32-year-old said. “And honestly, the adults need play more than kids.”
Yet while Black and brown mental health practitioners such as Fields have labored to address these issues within their communities, a very different conversation has been occurring in the nation at large.
For years, discussions about America’s substance-abuse crisis have focused almost exclusively on the narrative that it is white, middle-age adults who face the greatest risk of dying from drug overdoses, alcoholic liver disease and suicide.
The theory, which was presented by two Princeton economists in 2015 and based on data from 1999 to 2013, argued that despair was behind rising premature mortality rates among white Americans, especially those who were less educated.
Virtually overnight, the “deaths of despair” concept began to drive the national discourse over populist far-right politics; the rise of Donald Trump; and deepening political polarization over such topics as addiction treatment, law enforcement and immigration.
But after roughly a decade, researchers at UCLA and elsewhere have begun to dismantle this idea.
In a study published recently in the journal JAMA Psychiatry, authors found that deaths of despair rates for middle-age Black and Native Americans have surged past those of white Americans as the overdose crisis moves from being driven by prescription opioids to illegal drugs such as fentanyl and heroin.
While the opioid crisis did raise drug overdose deaths among white Americans for a time, it was an anomaly, said Joseph Friedman, a social medicine expert at UCLA’s David Geffen School of Medicine who was the lead author of the journal analysis. In fact, by 2022 the rate for white Americans had started to dip.
“What’s really important is that now, with these three causes of death, the gap has closed, and it’s moving in the other direction,” Friedman said.
Sandra Mims, a community health worker with Community Health Project L.A., puts out boxes of Narcan — a naloxone nasal spray that reverses the effects of opioid overdose — at an event at MacArthur Park in Los Angeles on International Overdose Awareness Day.
(Mel Melcon / Los Angeles Times)
The analysis found that deaths of despair for Black Americans hit a rate of 103.81 per 100,000 people in 2022, compared with 102.63 for white Americans. The rate for Native American and Alaska Native populations was even higher at 241.7 per 100,000 people in 2022.
The UCLA analysis doesn’t specify the midlife personal issues that might have led to addiction or suicide.
But the authors say that flaws in the methodology of the 2015 deaths of despair report skewed its conclusions about who was most at risk. Specifically, Friedman said that it failed to give enough consideration to long-standing racial inequities that Black Americans experience in income, educational attainment, incarceration and access to quality medical care, all of which can contribute to drug use and poor mental health outcomes. And statistics for Native Americans weren’t factored in at all.
“It was burned into the American psyche that it was white people in the rural U.S.,” Friedman said. “It was just a very small piece of the truth that was very interesting but was widely sold as something it wasn’t.”
Another recent worrying sign, Friedman says: Deaths of despair among Latinos are starting to catch up to those among Black and Native Americans.
Princeton professors Anne Case and her husband Angus Deaton, winner of the 2015 Nobel Prize in economic sciences, were thrust into the media spotlight when their deaths of despair findings were first published. Deaton told NPR that during a visit to the White House, even President Obama asked him about the phenomenon.
Their 2020 book, “Deaths of Despair and the Future of Capitalism,” was described by publisher Princeton University Press as “a troubling portrait of the American dream in decline.”
“For the white working class, today’s America has become a land of broken families and few prospects. As the college educated become healthier and wealthier, adults without a degree are literally dying from pain and despair,” the publisher said.
Fields, who employs yoga and pottery in her therapy, said this framing was misleading and racially biased.
“I’m actually flabbergasted that somebody has a term called ‘deaths of despair,’” Fields said. “It’s ‘despair’ when white people experience this suffering. But when we experience it, it’s just what we have to deal with.”
Nakeya Fields says it’s important to address mental wellness issues early, before people reach a crisis point and become another statistic.
(Jason Armond / Los Angeles Times)
Both Friedman and Fields say their critiques are not intended to minimize deaths among white Americans.
Still, Friedman wonders: “How do we empower Black and Native American communities in a way that enables them to treat these problems?”
Racism must be considered when trying to make sense of the crisis in premature deaths, says Dr. Helena Hansen, head of UCLA’s Department of Psychiatry and a senior author on Friedman’s analysis. Hansen, who is Black and specializes in addiction psychiatry, also co-authored the book “Whiteout: How Racial Capitalism Changed the Color of Opioids in America.”
For years, pharmaceutical companies steered expensive prescription pain medications, such as the opioid Oxycontin, as well as the most effective medications for opioid-use disorder, to white Americans with good access to healthcare, she said.
But at the same time, Black and brown Americans were unfairly subjected to law enforcement policies that prioritized incarceration for illegal drug use over increasing access to more humane medical strategies to help them, further harming already vulnerable communities, Hansen said.
“In our society, people with access to the new technologies and pharmaceuticals are more likely to be white,” Hansen says. “None of this is by accident. All of this is the direct result of careful racially and class-segmented marketing strategies by pharmaceutical companies.”
This two-tiered system arose because drug manufacturers, doctors and policymakers have for too long failed to see people from historically marginalized communities who live with addiction and mental health crises as worthy of the same sympathy and treatments that many white Americans receive, Hansen says.
Joseph Gone, a professor of anthropology at Harvard who has spent 25 years studying the intersection of colonialism, culture and mental health in Indigenous communities, agreed.
“Deaths of despair have been a reality for Indigenous communities since conquest and dispossession,” he said.
“It’s amazing how much grief our people contend with from early deaths — there are not that many communities in America that bear it quite the way we do,” said Gone, who is a member of the Aaniiih-Gros Ventre tribal nation of north-central Montana. “Until we acknowledge and take responsibility for the casualties of colonization, which endure to this day through deaths of despair, it’s going to be very hard to turn this around.”
Gone, who has collaborated with Friedman on previous research, says the mental health crisis in tribal nations is aggravated by widespread joblessness and generational poverty, and a lack of healthcare resources to treat people in need of immediate or long-term treatment.
Just one traveling psychiatrist serves reservations spread across both Montana and Wyoming — a region covering more than 243,300 square miles — mostly to manage patients’ prescriptions, he says.
And “for all of Indian country, we’re talking about a very small number of in-patient psychiatric facilities,” Gone says.
General practitioners can serve as a first line of defense, but they are not necessarily equipped to address the ongoing life crises that can lead to excessive drug and alcohol use, Gone says.
Fields says it’s important to address mental wellness issues early, before people reach a crisis point and become another statistic.
While her focus remains on Black women, she’s developed additional programming for adults, families and children, such as developmental screenings that measure for high stress levels. In June, Fields will co-present “Rap 4 Peace,” a conference and gala featuring hip-hop artists talking about mental health and reducing gun violence.
“This ‘tragedy of despair’ lives in us,” Fields says. “We breathe it. We go outside hoping that nobody will harm us or our children because they feel threatened by us. This is truly harmful to our bodies.”
Science
What’s in a Name? For These Snails, Legal Protection
The sun had barely risen over the Pacific Ocean when a small motorboat carrying a team of Indigenous artisans and Mexican biologists dropped anchor in a rocky cove near Bahías de Huatulco.
Mauro Habacuc Avendaño Luis, one of the craftsmen, was the first to wade to shore. With an agility belying his age, he struck out over the boulders exposed by low tide. Crouching on a slippery ledge pounded by surf, he reached inside a crevice between two rocks. There, lodged among the urchins, was a snail with a knobby gray shell the size of a walnut. The sight might not dazzle tourists who travel here to see humpback whales, but for Mr. Avendaño, 85, these drab little mollusks represent a way of life.
Marine snails in the genus Plicopurpura are sacred to the Mixtec people of Pinotepa de Don Luis, a small town in southwestern Oaxaca. Men like Mr. Avendaño have been sustainably “milking” them for radiant purple dye for at least 1,500 years. The color suffuses Mixtec textiles and spiritual beliefs. Called tixinda, it symbolizes fertility and death, as well as mythic ties between lunar cycles, women and the sea.
The future of these traditions — and the fate of the snails — are uncertain. The mollusks are subject to intense poaching pressure despite federal protections intended to protect them. Fishermen break them (and the other mollusks they eat) open and sell the meat to local restaurants. Tourists who comb the beaches pluck snails off the rocks and toss them aside.
A severe earthquake in 2020 thrust formerly submerged parts of their habitat above sea level, fatally tossing other mollusks in the snail’s food web to the air, and making once inaccessible places more available to poachers.
Decades ago, dense clusters of snails the size of doorknobs were easy to find, according to Mr. Avendaño. “Full of snails,” he said, sweeping a calloused, violet-stained hand across the coves. Now, most of the snails he finds are small, just over an inch, and yield only a few milliliters of dye.
Science
Video: This Parrot Has No Beak, But Is at the Top of the Pecking Order
new video loaded: This Parrot Has No Beak, But Is at the Top of the Pecking Order
By Meg Felling and Carl Zimmer
April 20, 2026
Science
Contributor: Focus on the real causes of the shortage in hormone treatments
For months now, menopausal women across the U.S. have been unable to fill prescriptions for the estradiol patch, a long-established and safe hormone treatment. The news media has whipped up a frenzy over this scarcity, warning of a long-lasting nationwide shortage. The problem is real — but the explanations in the media coverage miss the mark. Real solutions depend on an accurate understanding of the causes.
Reporters, pharmaceutical companies and even some doctors have blamed women for causing the shortage, saying they were inspired by a “menopause moment” that has driven unprecedented demand. Such framing does a dangerous disservice to essential health advocacy.
In this narrative, there has been unprecedented demand, and it is explained in part by the Food and Drug Administration’s recent removal of the “black-box warning” from estradiol patches’ packaging. That inaccurate (and, quite frankly, terrifying) label had been required since a 2002 announcement overstated the link between certain menopause hormone treatments and breast cancer. Right-sizing and rewording the warning was long overdue. But the trouble with this narrative is that even after the black-box warning was removed, there has not been unprecedented demand.
Around 40% of menopausal women were prescribed hormone treatments in some form before the 2002 announcement. Use plummeted in its aftermath, dipping to less than 5% in 2020 and just 1.8% in 2024. According to the most recent data, the number has now settled back at the 5% mark. Unprecedented? Hardly. Modest at best.
Nor is estradiol a new or complex drug; the patch formulation has existed for decades, and generic versions are widely manufactured. There is no exotic ingredient, no rare supply chain dependency, no fluke that explains why women are suddenly being told their pharmacy is out of stock month after month.
The story is far more an indictment of the broken insurance industry: market concentration, perverse incentives and the consequences of allowing insurance companies to own the pharmacy benefit managers that effectively control drug access for the majority of users. Three companies — CVS Caremark, Express Scripts and OptumRx — manage 79% of all prescription drug claims in the United States. Those companies are wholly owned subsidiaries of three insurance behemoths: CVS Health, Cigna and UnitedHealth Group, respectively. This means that the same corporation that sells you your insurance plan also decides which drugs get covered, at what price, and whether your pharmacy can stock them. This is called vertical integration. In another era, we might have called it a cartel. The resulting problems are not unique to hormone treatments; they have affected widely used medications including blood thinners, inhalers and antibiotics. When a low-cost generic such as estradiol — a medication with no blockbuster profit margins and no patent protection — runs into friction in this system, the friction is not random. It is structural. Every decision in that chain is filtered through the same corporate profit motive. And when the drug in question is an off-patent estradiol patch that has negligible profit margins because of generic competition but requires logistical investment to keep consistently in stock? The math on “how much does this company care about ensuring access” is not complicated.
Unfortunately, there is little financial incentive to ensure smooth, consistent access. There is, however, significant financial incentive to steer patients toward branded alternatives, or simply to let supply tighten — because the companies aren’t losing much profit if sales of that product dwindle. This is not a conspiracy theory: The Federal Trade Commission noted this dynamic in a report that documented how pharmacy benefit managers’ practices inflate costs, reduce competition and harm patient access, particularly for independent pharmacies and for generic drugs.
Any claim that the estradiol patch shortage is meaningfully caused by more women now demanding hormone treatments is a distraction. It is also misogyny, pure and simple, to imply that the solution to the shortage is for women’s health advocates to dial it down and for women to temper their expectations. The scarcity of estradiol patches is the outcome of a broken system refusing to provide adequate supply.
Meanwhile, there are a few strategies to cope.
- Ask your prescriber about alternatives. Estradiol is available in multiple formulations, including gel, spray, cream, oral tablet, vaginal ring and weekly transdermal patch, which is a different product from the twice-weekly patch and may be more consistently available depending on manufacturer and region.
- Consider an online pharmacy. Many are doing a good job locating and filling these prescriptions from outside the pharmacy benefit manager system.
- Call ahead. Patch shortages are inconsistent across regions and distributors. A call to pharmacies in your area, or a broader geographic radius if you’re able, can locate stock that your regular pharmacy doesn’t have.
- Consider a compounding pharmacy. These sources can sometimes meet needs when commercially manufactured products are inaccessible. The hormones used are the same FDA-regulated bulk ingredients.
Beyond those Band-Aid solutions, more Americans need to fight for systemic change. The FTC report exists because Congress asked for it and committed to legislation that will address at least some of the problems. The FDA took action to change the labeling on estrogen in the face of citizen and medical experts’ pressure; it should do more now to demand transparency from patch manufacturers.
Most importantly, it is on all of us to call out the cracks in the current system. Instead of repeating “there’s a patch shortage” or a “surge in demand,” say that a shockingly small minority of menopausal women still even get hormonal treatments prescribed at all, and three drug companies control the vast majority of claims in this country. Those are the real problems that need real solutions.
Jennifer Weiss-Wolf, the executive director of the Birnbaum Women’s Leadership Center at New York University School of Law, is the author of the forthcoming book “When in Menopause: A User’s Manual & Citizen’s Guide.” Suzanne Gilberg, an obstetrician and gynecologist in Los Angeles, is the author of “Menopause Bootcamp.”
-
New York1 hour agoN.Y.P.D. Narcotics Unit Under Review After a Beating Is Caught on Tape
-
Detroit, MI2 hours agoMI Healthy Climate Conference in Detroit focuses on green funding and strong future
-
San Francisco, CA2 hours agoCalifornia’s New Hotel Edit: The Best Places to Stay Across the Golden State in 2026
-
Dallas, TX2 hours agoThe Brandon Aubrey Deal | DZTV
-
Miami, FL2 hours agoRanking the Miami Heat’s Top Trade Targets
-
Boston, MA2 hours agoFormer Massachusetts doctor faces 81 new sexual assault charges
-
Denver, CO2 hours agoHouston County murder suspect returns to face charges after her arrest in Denver
-
Seattle, WA2 hours agoWest Seattle Tool Library to host annual tool sale this Saturday, April 25 | The White Center Blog